vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Koppers Holdings Inc. (KOP). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $432.7M, roughly 1.4× Koppers Holdings Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 6.9%, a 34.0% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs -9.3%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $28.5M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs -6.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Koppers is a global chemical and materials company based in Pittsburgh, Pennsylvania, United States. Its headquarters is an art-deco 1920s skyscraper, the Koppers Tower.
EXEL vs KOP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $432.7M |
| Net Profit | $244.5M | $29.7M |
| Gross Margin | 95.6% | 25.6% |
| Operating Margin | 39.3% | 11.5% |
| Net Margin | 40.8% | 6.9% |
| Revenue YoY | 5.6% | -9.3% |
| Net Profit YoY | 74.8% | 391.2% |
| EPS (diluted) | $0.89 | $1.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $432.7M | ||
| Q3 25 | $568.3M | $485.3M | ||
| Q2 25 | $555.4M | $504.8M | ||
| Q1 25 | $566.8M | $456.5M | ||
| Q4 24 | — | $477.0M | ||
| Q3 24 | $539.5M | $554.3M | ||
| Q2 24 | $637.2M | $563.2M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $29.7M | ||
| Q3 25 | $184.8M | $23.8M | ||
| Q2 25 | $159.6M | $16.4M | ||
| Q1 25 | $139.9M | $-13.9M | ||
| Q4 24 | — | $-10.2M | ||
| Q3 24 | $118.0M | $22.8M | ||
| Q2 24 | $226.1M | $26.8M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 25.6% | ||
| Q3 25 | 96.6% | 24.1% | ||
| Q2 25 | 96.5% | 22.6% | ||
| Q1 25 | 96.5% | 23.2% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | 96.8% | 21.9% | ||
| Q2 24 | 97.2% | 21.6% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 11.5% | ||
| Q3 25 | 37.6% | 10.7% | ||
| Q2 25 | 33.6% | 7.7% | ||
| Q1 25 | 28.8% | 5.9% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | 25.2% | 9.0% | ||
| Q2 24 | 43.3% | 10.2% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 6.9% | ||
| Q3 25 | 32.5% | 4.9% | ||
| Q2 25 | 28.7% | 3.2% | ||
| Q1 25 | 24.7% | -3.0% | ||
| Q4 24 | — | -2.1% | ||
| Q3 24 | 21.9% | 4.1% | ||
| Q2 24 | 35.5% | 4.8% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $1.44 | ||
| Q3 25 | $0.65 | $1.17 | ||
| Q2 25 | $0.55 | $0.81 | ||
| Q1 25 | $0.47 | $-0.68 | ||
| Q4 24 | — | $-0.47 | ||
| Q3 24 | $0.40 | $1.09 | ||
| Q2 24 | $0.77 | $1.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | $928.3M |
| Stockholders' EquityBook value | $2.2B | $574.0M |
| Total Assets | $2.8B | $1.9B |
| Debt / EquityLower = less leverage | — | 1.62× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $928.3M | ||
| Q3 25 | — | $932.9M | ||
| Q2 25 | — | $977.5M | ||
| Q1 25 | — | $989.0M | ||
| Q4 24 | — | $939.5M | ||
| Q3 24 | — | $989.4M | ||
| Q2 24 | — | $1.0B |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $574.0M | ||
| Q3 25 | $2.0B | $545.6M | ||
| Q2 25 | $2.1B | $526.8M | ||
| Q1 25 | $2.2B | $498.0M | ||
| Q4 24 | — | $488.7M | ||
| Q3 24 | $2.3B | $532.3M | ||
| Q2 24 | $2.1B | $509.2M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $1.9B | ||
| Q3 25 | $2.7B | $1.9B | ||
| Q2 25 | $2.8B | $1.9B | ||
| Q1 25 | $2.9B | $1.9B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | $3.0B | $2.0B | ||
| Q2 24 | $2.8B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.62× | ||
| Q3 25 | — | 1.71× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | — | 1.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $45.1M |
| Free Cash FlowOCF − Capex | $332.4M | $28.5M |
| FCF MarginFCF / Revenue | 55.5% | 6.6% |
| Capex IntensityCapex / Revenue | 0.2% | 3.8% |
| Cash ConversionOCF / Net Profit | 1.36× | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $67.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $45.1M | ||
| Q3 25 | $49.0M | $49.6M | ||
| Q2 25 | $211.4M | $50.5M | ||
| Q1 25 | $240.3M | $-22.7M | ||
| Q4 24 | — | $74.7M | ||
| Q3 24 | $271.3M | $29.8M | ||
| Q2 24 | $119.5M | $27.2M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $28.5M | ||
| Q3 25 | $46.2M | $37.6M | ||
| Q2 25 | $208.5M | $38.4M | ||
| Q1 25 | $236.3M | $-37.0M | ||
| Q4 24 | — | $56.1M | ||
| Q3 24 | $263.1M | $14.4M | ||
| Q2 24 | $113.0M | $10.1M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 6.6% | ||
| Q3 25 | 8.1% | 7.7% | ||
| Q2 25 | 37.5% | 7.6% | ||
| Q1 25 | 41.7% | -8.1% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | 48.8% | 2.6% | ||
| Q2 24 | 17.7% | 1.8% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 3.8% | ||
| Q3 25 | 0.5% | 2.5% | ||
| Q2 25 | 0.5% | 2.4% | ||
| Q1 25 | 0.7% | 3.1% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | 1.5% | 2.8% | ||
| Q2 24 | 1.0% | 3.0% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.52× | ||
| Q3 25 | 0.27× | 2.08× | ||
| Q2 25 | 1.32× | 3.08× | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.30× | 1.31× | ||
| Q2 24 | 0.53× | 1.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
KOP
| Other | $127.8M | 30% |
| Railroad Treated Products | $119.0M | 28% |
| Utility Poles | $79.8M | 18% |
| Pitch And Related Products | $74.1M | 17% |
| Carbon Black Feedstock And Distillates | $14.4M | 3% |
| Railroad Infrastructure Products And Services | $9.9M | 2% |
| Phthalic Anhydride Naphthalene And Other Chemicals | $7.7M | 2% |
